Federal health regulators have rejected an application filed by Acadia Pharmaceuticals to expand the use of its blockbuster antipsychotic drug, Nuplazid, highlighting concerns that the medication may not be effective…
An ISMP report questions the FDA conclusions that there are no new safety signals with the Parkinson's disease psychosis drug, Nuplazid.
The FDA has launched a new safety review of the Parkinson's disease drug Nuplazid, FDA Commissioner Scott Gottlieb told Congress last week.
More than 700 deaths have been linked to Nuplazid side effects, raising concerns about the safety of the Parkinson's disease drug.